Humanigen, Inc. (HGENQ)
Jul 15, 2024 - HGENQ was delisted (reason: shares cancelled)
0.0002
0.00 (0.00%)
Inactive · Last trade price on Jul 11, 2024
Humanigen Revenue
Humanigen had revenue of $221.00K in the quarter ending March 31, 2023, a decrease of -78.67%. This brings the company's revenue in the last twelve months to $1.70M, down -59.01% year-over-year. In the year 2022, Humanigen had annual revenue of $2.51M, down -30.07%.
Revenue (ttm)
$1.70M
Revenue Growth
-59.01%
P/S Ratio
0.01
Revenue / Employee
$283,167
Employees
6
Market Cap
23.82K
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2022 | 2.51M | -1.08M | -30.07% |
| Dec 31, 2021 | 3.60M | 3.28M | 1,052.24% |
| Dec 31, 2020 | 312.00K | - | - |
| Dec 31, 2019 | 0 | - | - |
| Dec 31, 2018 | 0 | - | - |
| Dec 31, 2017 | 0 | - | - |
| Dec 31, 2016 | 0 | - | - |
| Dec 31, 2015 | 0 | - | - |
| Dec 31, 2014 | 0 | - | - |
| Dec 31, 2013 | 44.00K | -6.05M | -99.28% |
| Dec 31, 2012 | 6.10M | -14.16M | -69.89% |
| Dec 31, 2011 | 20.26M | 2.54M | 14.36% |
| Dec 31, 2010 | 17.71M | 17.12M | 2,907.13% |
| Dec 31, 2009 | 589.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionHGENQ News
- 1 year ago - US says former Humanigen chief scientific officer charged with insider trading - Reuters
- 2 years ago - COVID-19 treatment developer Humanigen files for Chapter 11 bankruptcy - Reuters
- 2 years ago - Humanigen Announces First Participant Dosed in RATinG Trial of Lenzilumab for Early Treatment of Acute Graft Versus Host Disease Following Allogeneic Stem Cell Transplantation - Newsfile Corp
- 2 years ago - Humanigen Presents Promising New Hematologic Data from PREACH-M Trial for Chronic Myelomonocytic Leukemia Treatment at the 2023 European Hematology Association Congress - Newsfile Corp
- 2 years ago - Humanigen - Lenzilumab Being Studied as a Potential First Treatment in Thirty Years with a Novel Mechanism of Action for Chronic Myelomonocytic Leukemia (CMML), an Orphan Form of Leukemia - Newsfile Corp
- 3 years ago - Humanigen Reports Third Quarter 2022 Financial Results - Newsfile Corp
- 3 years ago - Humanigen Announces Participation and Presentation at Jefferies London Healthcare Conference - Newsfile Corp
- 3 years ago - Humanigen Announces Retention of SC&H Capital as Financial Advisor - Newsfile Corp